{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Subject&page=10",
    "query": {
      "condition": "Healthy Subject",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 6533,
    "total_pages": 654,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Subject&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Subject&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T22:44:20.413Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05192369",
      "title": "A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "CTP-543",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Concert Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 48,
      "start_date": "2022-01-04",
      "completion_date": "2022-01-28",
      "has_results": false,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05192369"
    },
    {
      "nct_id": "NCT05066113",
      "title": "Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hidradenitis Suppurativa",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Radiofrequency-Based treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "22 Years to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2017-08-15",
      "completion_date": "2026-03-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05066113"
    },
    {
      "nct_id": "NCT02364882",
      "title": "A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Female Sexual Health"
      ],
      "interventions": [
        {
          "name": "Sildenafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Strategic Science & Technologies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 65 Years · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2015-01",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-06-22",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02364882"
    },
    {
      "nct_id": "NCT03827642",
      "title": "A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Treatment A: Naloxone Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Naloxone Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Treatment C: Naloxone HCl Intravenous (IV) Injection",
          "type": "DRUG"
        },
        {
          "name": "Treatment D: Naloxone HCl Intramuscular (IM) Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-04-23",
      "completion_date": "2018-05-06",
      "has_results": false,
      "last_update_posted_date": "2019-02-01",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03827642"
    },
    {
      "nct_id": "NCT04084769",
      "title": "Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Immunisation (Healthy Volunteers)"
      ],
      "interventions": [
        {
          "name": "Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal Group B vaccine (Trumenba®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal group B vaccine (Bexsero®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "13 Years to 26 Years"
      },
      "enrollment_count": 570,
      "start_date": "2019-09-03",
      "completion_date": "2020-09-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Bridgeton",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04084769"
    },
    {
      "nct_id": "NCT00098969",
      "title": "UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "resveratrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2004-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-12-17",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098969"
    },
    {
      "nct_id": "NCT02265783",
      "title": "Sensor Off Study Using a Nellcor USB Pulse Oximetry Monitor Interface Cable",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Nellcor USB Pulse Oximeter Monitor Interface Cable",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic - MITG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-09",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2017-05-01",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "Boulder, Colorado",
      "locations": [
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02265783"
    },
    {
      "nct_id": "NCT00648713",
      "title": "Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Terbinafine Hydrochloride Tablets 250 mg",
          "type": "DRUG"
        },
        {
          "name": "Lamisil® Tablets 250 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2004-02",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648713"
    },
    {
      "nct_id": "NCT02095860",
      "title": "Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "DCV 3DAA FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-04",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-10-10",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02095860"
    },
    {
      "nct_id": "NCT04803682",
      "title": "A Smoking Prevention Program (ASPIRE) and Mentoring for Preventing Smoking Among High School Youths",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy Subject"
      ],
      "interventions": [
        {
          "name": "Preventive Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "13 Years to 18 Years"
      },
      "enrollment_count": 94,
      "start_date": "2016-01-08",
      "completion_date": "2021-03-16",
      "has_results": false,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-10-21T22:44:20.413Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04803682"
    }
  ]
}